ACE-031 1mg

1. What is ACE-031?

ACE-031 is a recombinant peptide designed to inhibit myostatin, a negative regulator of muscle growth. It works by binding to myostatin and preventing its interaction with the activin receptor type II, thus promoting muscle growth and regeneration. ACE-031 has been studied primarily for its potential in treating muscle-wasting diseases, such as muscular dystrophy, and for enhancing muscle mass in healthy individuals.

2. ACE-031 Structure

Sequence: H-Ile-Glu-Gly-Asp-Ala-Pro-Lys-Pro-Ala-His-Pro-Ile-OH

Molecular Formula: C₁₃₃H₂₂₇N₄₃O₃₃

Molecular Weight: 2,956.5 g/mol

3. ACE-031 Research

ACE-031: Powerful Myostatin Inhibitor Peptide

ACE-031 is a soluble Activin receptor IIB (ActRIIB)-Fc fusion protein that acts as a potent myostatin inhibitor. By “decoying” and neutralizing myostatin—a key negative regulator of muscle growth—ACE-031 promotes lean muscle gain, fat reduction, and bone health improvement, all demonstrated in both animal models and early human trials.

【1】 Muscle Growth & Lean Mass Enhancement

In a Phase 1 trial involving healthy postmenopausal women, a single dose of ACE-031 (3 mg/kg s.c.) was well tolerated, resulting in a 3.3% increase in total body lean mass (by DXA) and a 5.1% increase in thigh muscle volume (by MRI) within 29 days. These changes were accompanied by favorable shifts in bone and fat metabolism biomarkers (https://pubmed.ncbi.nlm.nih.gov/23169607/).

【2】Mechanism: Decoy Receptor for Myostatin

ACE-031 functions by blocking multiple ligands of the Transforming Growth Factor-β superfamily—especially myostatin, but also activin A and others—via its soluble ActRIIB-Fc “decoy receptor”. This effectively releases the inhibition on muscle growth and supports bone formation and fat metabolism regulation

【3】Animal Data: Metabolism, Strength & Bone Density

In mice, ACE-031 administration led to increased oxidative muscle metabolism, enhanced exercise endurance, and muscle strength gains (↑ 25–40%)—potentially via improved mitochondrial function (https://pubmed.ncbi.nlm.nih.gov/27416839/).

It also promoted fat oxidation, reduced adipose tissue, and stimulated bone mineral density (BMD) by suppressing osteoclast activity

【4】Potential in Muscle-Wasting Disorders & Cancer
ACE-031 has demonstrated promising trends in muscle wasting conditions:

In Duchenne muscular dystrophy (DMD) boys, ACE-031 preserved lean body mass and improved 6-minute walk test results.

In preclinical cancer models, ACE-031 showed potential to support muscle health and combat cachexia, possibly enhancing quality of life in cancer patients (https://pubmed.ncbi.nlm.nih.gov/23169607/).

Why Choose ACE-031?

ACE-031 offers a multi-faceted peptide solution:

✅ Lean Muscle Gain without exercise

✅ Fat Metabolism Support via enhanced oxidation

✅ Bone Health Improvement through osteoclast inhibition

✅ Clinical Validation in humans and animals

4. Future ACE-031 Research

The future of ACE-031 research is poised to explore its therapeutic potential in treating muscle-wasting disorders, especially Duchenne Muscular Dystrophy (DMD), sarcopenia, and other cachexia-related conditions. Since ACE-031 functions as a myostatin inhibitor—a protein that naturally limits muscle growth—blocking this pathway may help patients preserve or rebuild muscle mass. Researchers are especially interested in the long-term safety and efficacy of ACE-031 analogs in both rare pediatric neuromuscular diseases and age-related muscle decline.

One of the most promising directions involves combining ACE-031 with other anabolic agents or exercise interventions to amplify muscle gains in clinical scenarios. Preliminary human trials showed encouraging results before being halted due to mild adverse effects such as nosebleeds and gum bleeding, suggesting the need for further optimization of dosing protocols and delivery methods.

In the coming years, future studies may also evaluate the impact of ACE-031 on metabolic health, including insulin sensitivity, glucose uptake, and body composition in obese or diabetic populations. There is increasing scientific interest in how myostatin inhibition might regulate adipose tissue and energy balance, possibly contributing to improved metabolic flexibility. Moreover, advancements in peptide engineering could yield newer ACE-031 variants with enhanced specificity, reduced side effects, and improved bioavailability. As of now, ACE-031 remains a molecule of great interest in preclinical and experimental settings, with potential applications that extend beyond muscle growth and into overall physical resilience and rehabilitation support.

While official human therapeutic use is not currently approved, researchers continue to explore its clinical promise through peer-reviewed preclinical models and biomolecular studies.

Related Source:

• NIH Clinical Trials Database (Archived ACE-031 Study)【https://clinicaltrials.gov/study/NCT01099761】
• PubMed – Myostatin pathway inhibition

【https://pubmed.ncbi.nlm.nih.gov/20085968/】

5. Expert Insights on ACE-031

“ACE-031 use demonstrated trends for pharmacodynamic effects on lean mass, fat mass, BMD, and 6MWT.”

This official conclusion comes from a randomized, placebo-controlled study in Muscle & Nerve (2017), emphasizing how ACE-031 increased lean body mass, improved bone mineral density (BMD), and maintained 6-minute walk test (6MWT) performance.

“ACE-031 promotes muscle growth by binding to myostatin and other negative regulators of muscle mass.”

This statement, from IronMagazine, succinctly describes the core mechanism of action—ACE-031 neutralizes myostatin and related growth-inhibiting ligands, enabling enhanced muscle development.

These quotes underscore ACE-031’s potential to:

Significantly increase muscle mass and bone density

Counteract negative regulatory proteins via its myostatin-blocking mechanism

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.